Company Description
Axe Compute Inc. provides access to graphics processing unit and digital asset treasury strategy.
The company operates through two segments: Compute Services and Treasury Management; and Drug Discovery Services.
The Compute Services and Treasury Management segment provides access to graphics processing unit compute capacity and digital asset treasury strategy focused on Aethir token.
The Drug Discovery Services segment engages in the application of AI using its proprietary biobank of 150,000+ tumor samples, as well as creation of proprietary 3D culture models used in drug development.
The company was formerly known as Predictive Oncology Inc. and changed its name to Axe Compute Inc. in December 2025.
Axe Compute Inc. was incorporated in 2002 and is based in Pittsburgh, Pennsylvania.
| Country | United States |
| Founded | 2002 |
| Industry | Software - Infrastructure |
| Sector | Technology |
| Employees | 14 |
| CEO | Christopher Miglino |
Contact Details
Address: 91 43rd Street, Suite 110 Pittsburgh, Pennsylvania 15201 United States | |
| Phone | 412 432 1500 |
| Website | axecompute.com |
Stock Details
| Ticker Symbol | AGPU |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001446159 |
| CUSIP Number | 74039M408 |
| ISIN Number | US74039M4087 |
Key Executives
| Name | Position |
|---|---|
| Christopher Miglino | Chief Executive Officer and Director |
| Kyle Okamoto | President |
| Jeremy Yaukey-Witter | Co-Chief Financial Officer |
| Sara Turken J.D. | General Counsel |
| Dr. Lawrence J. DeLucas D.Sc, O.D, Ph.D. | Senior Vice President of Biologics |
| Dr. Arlette H. Uihlein FCAP, M.D. | Senior Vice President of Translational Medicine and Drug Discovery and Medical Director |